DK210784A - Konjugater af vinblastin eller vinblastinderivater og fremgangsmaade til fremstilling deraf - Google Patents

Konjugater af vinblastin eller vinblastinderivater og fremgangsmaade til fremstilling deraf Download PDF

Info

Publication number
DK210784A
DK210784A DK210784A DK210784A DK210784A DK 210784 A DK210784 A DK 210784A DK 210784 A DK210784 A DK 210784A DK 210784 A DK210784 A DK 210784A DK 210784 A DK210784 A DK 210784A
Authority
DK
Denmark
Prior art keywords
derivatives
conjugates
image
winblastin
vinblastin
Prior art date
Application number
DK210784A
Other languages
Danish (da)
English (en)
Other versions
DK210784D0 (da
Inventor
Andre Benoit Leon Trouet
Kandukuri Sivaprasada Bush Rao
Jean Alfred Alphonse Hannart
Jean-Paul Dejonghe
Original Assignee
Omnichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from LU84784A external-priority patent/LU84784A1/fr
Priority claimed from LU85161A external-priority patent/LU85161A1/fr
Application filed by Omnichem Sa filed Critical Omnichem Sa
Publication of DK210784D0 publication Critical patent/DK210784D0/da
Publication of DK210784A publication Critical patent/DK210784A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK210784A 1983-04-29 1984-04-27 Konjugater af vinblastin eller vinblastinderivater og fremgangsmaade til fremstilling deraf DK210784A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU84784A LU84784A1 (fr) 1983-04-29 1983-04-29 Nouveaux conjugues proteiques de la vinblastine leur procede de preparation et leur utilisation therapeutique
LU85161A LU85161A1 (fr) 1983-12-29 1983-12-29 Nouveaux conjugues de la vinblastine,leur procede de preparation et leur utilisation therapeutique

Publications (2)

Publication Number Publication Date
DK210784D0 DK210784D0 (da) 1984-04-27
DK210784A true DK210784A (da) 1984-10-30

Family

ID=26640299

Family Applications (1)

Application Number Title Priority Date Filing Date
DK210784A DK210784A (da) 1983-04-29 1984-04-27 Konjugater af vinblastin eller vinblastinderivater og fremgangsmaade til fremstilling deraf

Country Status (13)

Country Link
US (1) US4870162A (he)
EP (1) EP0124502B1 (he)
AT (1) ATE64396T1 (he)
AU (1) AU575819B2 (he)
CA (1) CA1234800A (he)
DE (1) DE3484691D1 (he)
DK (1) DK210784A (he)
ES (1) ES531965A0 (he)
GR (1) GR81790B (he)
HU (1) HUT34212A (he)
NZ (1) NZ207992A (he)
OA (1) OA07711A (he)
PT (1) PT78508B (he)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK167984A (da) * 1983-03-30 1984-10-01 Lilly Industries Ltd Alkaloidderivater
GB2181126B (en) * 1983-03-30 1987-08-26 Lilly Industries Ltd Novel pharmaceutical compounds
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4667030A (en) * 1985-06-17 1987-05-19 Eli Lilly And Company Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant
ATE89567T1 (de) * 1985-11-12 1993-06-15 Wallone Region Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2608158B2 (fr) * 1986-12-12 1992-03-27 Ire Celltarg Sa Nouveaux derives de vinblastine et composition pharmaceutique les contenant
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
US4728183A (en) * 1986-10-01 1988-03-01 Ocular Instruments, Inc. Ophthalmic lens for observing the fundus of the eye
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5007729A (en) * 1989-10-27 1991-04-16 Ocular Instruments, Inc. Wide angle ophthalmic lens
US5189450A (en) * 1991-05-21 1993-02-23 Ocular Instruments, Inc. High magnification ophthalmic lens
US5309187A (en) * 1992-03-18 1994-05-03 Ocular Instruments, Inc. High magnification ophthalmic lens
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
DE69233126T2 (de) * 1992-09-25 2004-04-15 Neorx Corp., Seattle Therapeutischer inhibitor der vaskulären glatten muskelzellen
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
CA2203622C (en) * 1994-08-19 2011-11-01 Andre Trouet Compounds, pharmaceutical composition and diagnostic device comprising them and their use
US5623323A (en) * 1994-10-26 1997-04-22 Ocular Instruments, Inc. Extra wide field ophthalmic lens
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6127333A (en) * 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CN1181092C (zh) * 1997-12-02 2004-12-22 麦克公司 可用于治疗前列腺癌的缀合物
US20040081659A1 (en) * 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) * 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
AU5240999A (en) * 1998-07-31 2000-02-21 Goldsmith Seeds Inc. Trimeric and polymeric alkaloids
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
CA2413149A1 (en) 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds with isoleucine
US20030232760A1 (en) * 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
WO2003106659A2 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP2517730A3 (en) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20090105172A1 (en) * 2005-03-07 2009-04-23 Diener John L Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2481427A1 (en) 2007-03-14 2012-08-01 Endocyte, Inc. Folate-Tubulysin conjugates
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1037379A (en) * 1965-01-11 1966-07-27 Lilly Co Eli Desacetyl polynuclear indoles
FR2349335A1 (fr) * 1976-04-28 1977-11-25 Inst Int Pathologie Cellulaire Complexes d'alcaloides bis-indoliques du type vinblastine avec la tubuline, leur procede d'obtention et leur utilisation
US4096148A (en) * 1976-12-06 1978-06-20 Eli Lilly And Company Oxazolidinedione derivatives of Vinca alkaloids
US4357334A (en) * 1980-03-20 1982-11-02 Eli Lilly And Company Use of VLB 3-(2-chloroethyl) carboxamide in treating neoplasms
LU83822A1 (fr) * 1981-12-08 1983-09-01 Omnichem Sa Derives n-(vinblastinoyl-23)d'acides amines,leur preparation et leur application therapeutique
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
DK167984A (da) * 1983-03-30 1984-10-01 Lilly Industries Ltd Alkaloidderivater
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates

Also Published As

Publication number Publication date
EP0124502A3 (en) 1986-05-07
ES8600769A1 (es) 1985-11-01
DK210784D0 (da) 1984-04-27
ES531965A0 (es) 1985-11-01
GR81790B (he) 1984-12-12
PT78508A (en) 1984-05-01
DE3484691D1 (de) 1991-07-18
CA1234800A (en) 1988-04-05
AU575819B2 (en) 1988-08-11
EP0124502B1 (fr) 1991-06-12
AU2743484A (en) 1984-11-01
ATE64396T1 (de) 1991-06-15
OA07711A (fr) 1985-06-30
PT78508B (en) 1986-05-20
HUT34212A (en) 1985-02-28
US4870162A (en) 1989-09-26
NZ207992A (en) 1987-04-30
EP0124502A2 (fr) 1984-11-07

Similar Documents

Publication Publication Date Title
DK210784D0 (da) Konjugater af vinblastin eller vinblastinderivater og fremgangsmaade til fremstilling deraf
BR9509665A (pt) Composto composições e métodos
DK296087D0 (da) Peptidmateriale og fremgangsmaade til paavisning af antistoffer til htlv-iii
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
CA2232626A1 (en) Novel affinity ligands and their use
FR2546164B1 (fr) Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
FI945705A0 (fi) Bisindolyylimaleimidien parannettu synteesi
IL76877A (en) Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
ATE51617T1 (de) Verfahren zur herstellung von 4-phenyl-pyrrolderivaten.
PT87537A (pt) Process for the preparation of cyclic anticoagulant peptides
DK1181366T4 (da) Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder
ES8601483A1 (es) Un metodo de inmunoensayo para determinar la lidocaina o un derivado relacionado de la misma en una muestra a ensayar
IL77116A (en) Process for synthesizing peptides
FI97226C (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-amino-substituoitujen oktahydro-1,7,8-indolitsiinitriolijohdannaisten valmistamiseksi
DK166391C (da) Analogifremgangsmaade til fremstilling af bis-thymosin-alfa1-forbindelser
ES2150443T3 (es) Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
DK164107C (da) Konjugater af vinblastin eller derivater deraf, fremgangsmaader til deres fremstilling og farmaceutiske praeparater indeholdende dem
ATE197709T1 (de) Methadonderivate und protein- und polypeptid- methadonkonjugate und markierte verbindungen
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
NZ215994A (en) Culturing e.coli to produce interferon alpha and gamma and interleukin-2
ES2038780T3 (es) Procedimiento para la preparacion de nuevos compuestos triciclicos.
GB2001066A (en) Preparation of benzylidene derivatives
EA199800274A1 (ru) Способ получения бензилзамещенных производных роданина
ES447686A1 (es) Procedimiento para la preparacion de tripeptidos derivados de la l-prolina.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment